


## Hawaii Headache Center awarded Hawaii's First Research to Investigate Treatment of Menstrual Migraine in Hawaii's Women with Ubrogepant

Migraine is one of the most common neurological conditions, especially among women. According to the American Migraine Foundation, two out of three women with migraine experience attacks that are linked to their menstrual cycle. These are called menstrual migraines, and they typically begin within two days before the start of menstruation and up to three days after bleeding begins. Menstrual migraine attacks tend to be more intense, longer lasting, and more resistant to treatment than migraines that occur at other times of the month. One of the main drivers of menstrual migraine is the sharp drop in estrogen levels that occurs just before menstruation. This hormonal shift may influence brain chemicals involved in migraine, making treatment more difficult during this time.



**Ubrogepant**, an FDA-approved treatment for acute migraine, is now being studied as a potential option for the **short-term prevention of menstrual migraine**. In this clinical trial, about 450 adult women who experience menstrual migraine will be enrolled across approximately 100 locations in the U.S., including the [Hawaii Headache and Facial Pain Center](#). Participants will be randomly assigned to receive either **ubrogepant** or a **placebo** during the high-risk days of their menstrual cycle. The goal of the study is to evaluate whether ubrogepant can reduce the frequency or severity of menstrual migraine attacks when taken preventively during this time.

*Who qualifies? 1-year history of migraine or longer, migraine attacks in at least 2 of 3 perimenstrual periods, Less than 15 headache days per month*

[Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension.](#)

For more information, See [NIH Info](#) or contact: [Hawaii Headache & Facial Pain Center](#) & [Hawaii Headache Research Unit](#), 2230 Liliha Street #104, HONOLULU, HI 96817, Research Hotline (808) 564-6141 [info@HawaiiNeuroscience.com](mailto:info@HawaiiNeuroscience.com)



CLINICAL TRIALS



"Our team of neurologists, neuroscience specialists and researchers in Hawaii are excited to take part in this clinical trial studying Ubrelyv for menstrual migraine. It's an important step toward expanding treatment options for women who experience debilitating attacks around their menstruation, and we're proud to support research that could truly make a difference." [Eonjung Angeline Kim, MD](#), Investigator & Director, [Hawaii Headache & Facial Pain Center](#) & [Hawaii Headache Research Unit](#), Hawaii Pacific Neuroscience, Clinical Assistant Professor of Medicine (Neurology), University Hawaii JABSOM